Navigation auf


URPP Translational Cancer Research


Announcement: The URPP “Translational Cancer Research” has closed most activities by 31.12.2022

Although our URPP officially runs until 31.12.2024, de facto most activities were closed at the end of 2022. As all URPPs receive half of the budget for the final 4 years, our consortium decided to work during the last 2 years with full power rather 4 years on half-flame.

We are very proud of our sustainable achievements. These were only possible thanks to the support and trust from the University of Zurich and inputs from the scientific community in Zurich.
Thank you.

Our final report will be published on this site in due time.

Read about how work by Steve Pascolo and colleagues on mRNA and the SARS-CoV-2 vaccine may contribute to the cure of cancer.

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Read about the contribution of Steve Pascolo to developing a Corona-vaccine here:

Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells

Development of Corona vaccine at a rapid pace

Vaccines are needed in the fight against the new sars corona virus. Thanks to new technologies, Steve Pascolo, who works at the University of Zurich and is a member of out URPP consortium, can produce vaccine candidates within a very short time. Initial clinical trials based on the same method are already underway abroad.

UZH News

UZH News
Greater Zurich Area

Schadt et al discovered that cancer-cell-intrinsic expression of cGAS contributes to tumor immunogenicity

Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation

Loss of Cilia Leads to Melanoma

New Biomarkers Predict Outcome of Cancer Immunotherapy

Shedding Light on Cause of Resistance to Tumor Immunotherapy

Swiss Bridge Award for Prof. Dr. Christian Mosimann and Dr. Alexa Burger (IMLS).

Prof. Dr. Christian Mosimann and Dr. Alexa Burger received the Swiss Bridge Award for their work on zebrafish cancer models. The seed grant from the URPP “Translational Cancer Research” enabled collection of preliminary data and fruitful collaborations with URPP-linked labs, both of which were instrumental to winning the Swiss Bridge Award.

Swiss Bridge Award 2016 (PDF, 185 KB)

URPP received continued funding for 2017-2020 of 11 Mio CHF

The University of Zurich has decided to support the URPP "Translational Cancer Research" for 4 more years with CHF 11'000'000. The URPP received the first funding in 2013, which was about 60% of this amount.